This is a global, multicenter, placebo-controlled, phase 3 study evaluating the efficacy and safety of riliprubart in adult participants with CIDP who are refractory or had an insufficient response to standard of care (SOC) therapies, defined as Ig administered IV (IVIg) or SC (SCIg), or corticosteroids. Treatment duration will be 48 weeks. Participant must…
We are doing a study to learn more about the progression of knee osteoarthritis (OA). We are recruiting patients (Men 45-85 years old; Women 55-85 years old) who may or may not have OA of the knee(s). This study involves a screening and enrollment visit with annual visits for 3 years. Study activities include a hip and knee assessment, questionnaires, two…
Depression and some antidepressants may be associated with an increased risk of breaking a bone. It is not clear why this could be the case. It is possible that depression and/or certain medications used for the treatment of depression cause bone loss, increase the risk of falls, are associated with lower physical activity, or effects on muscle function.…